AstraZeneca's Imfinzi combination fails advanced lung cancer study
(Reuters) - AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations.
The clinical trial, called NEPTUNE, was testing Imfinzi along with tremelimumab and comparing the combination to platinum-based chemotherapy to treat patients whose cancer had spread to other parts of the body.
London-listed AstraZeneca said though the trial involved a wide range of patients, the primary group being tested had high levels of mutations in their DNA.
The combination treatment did not meet the main goal of improving overall survival in the primary group, the company said.
Mutations in tumors are measured using a system called tumor mutational burden (TMB) and the primary group had TMB of 20 or more.
Imfinzi belongs to the immunotherapy class of treatments that boost the body's own immune system to fight cancer, and tumors with high levels of TMB may be more visible to the immune system.
Rival immunotherapies include Bristol-Myers Squibb's Opdivo.
NSCLC accounts for up to 85% of lung cancers, by far the leading cause of cancer death among men and women, according to the American Cancer Society.
(The story corrects paragraph two to remove reference to tremelimumab as 'FDA-approved'.)
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Arun Koyyur and Patrick Graham)
© Copyright Reuters Ltd. All rights reserved. The information contained in this news report may not be published, broadcast or otherwise distributed without the prior written authority of Reuters Ltd.